Introduction {#jcmm12797-sec-0001}
============

Acute myocardial infarction (AMI) is a common and life‐threatening clinical condition globally [1](#jcmm12797-bib-0001){ref-type="ref"}, [2](#jcmm12797-bib-0002){ref-type="ref"}. More than seven million persons suffer from the disease each year [3](#jcmm12797-bib-0003){ref-type="ref"}. Acute myocardial infarction usually occurs as a result of ruptured atherosclerotic plaque, platelet‐mediated thrombosis and prolonged myocardial ischaemia [4](#jcmm12797-bib-0004){ref-type="ref"}, [5](#jcmm12797-bib-0005){ref-type="ref"}. Antiplatelet drug clopidogrel is an appropriate and immediate treatment for AMI, and should be used for long‐term to prevent recurrent ischaemic events [6](#jcmm12797-bib-0006){ref-type="ref"}, [7](#jcmm12797-bib-0007){ref-type="ref"}.

However, some patients receive clopidogrel treatment, but still experience recurrent angina pectoris and AMI. Previous studies revealed significant interindividual variability in clopidogrel effect on platelet aggregation [8](#jcmm12797-bib-0008){ref-type="ref"}, [9](#jcmm12797-bib-0009){ref-type="ref"}, [10](#jcmm12797-bib-0010){ref-type="ref"}, which might inevitably lead to various clinical effectivenesses.

Clopidogrel is a prodrug, and requires multiple cytochrome (CYP) P450 isoenzymes for its activation, such as CYP1A2 and CYP2C19 [11](#jcmm12797-bib-0011){ref-type="ref"}. Among these isoenzymes, the CYP2C19 is considered to be an extremely important enzyme in clopidogrel transformation [12](#jcmm12797-bib-0012){ref-type="ref"}. Hulot *et al*. reported that the CYP2C19\*2 loss‐of‐function allele was associated with a marked decrease in platelet responsiveness to clopidogrel [13](#jcmm12797-bib-0013){ref-type="ref"}, and such single nucleotide polymorphism might partially explain the variability in clopidogrel effects. But another study showed no such relationship between the CYP2C19 genotype and the antiplatelet effect of clopidogrel [14](#jcmm12797-bib-0014){ref-type="ref"}. Thus, there was still insufficient evidence to determine the clinical impact of the CYP2C19\*2 loss‐of‐function mutation.

Apart from genetic polymorphism, there are almost certainly other factors which can lead to the variability in clopidogrel effectiveness, such as percutaneous coronary intervention (PCI) and race [15](#jcmm12797-bib-0015){ref-type="ref"}, [16](#jcmm12797-bib-0016){ref-type="ref"}, [17](#jcmm12797-bib-0017){ref-type="ref"}, [18](#jcmm12797-bib-0018){ref-type="ref"}. Another compelling and unexpected factor is cigarette smoking. Smoking has the ability to increase the expression of the CYP1A2 [19](#jcmm12797-bib-0019){ref-type="ref"}, which is one of the CYP P450 isoenzymes for clopidogrel activation. Bliden *et al*. proved that the clopidogrel treatment in current smokers was associated with the increased platelet inhibition and the lower aggregation compared with non‐smokers [20](#jcmm12797-bib-0020){ref-type="ref"}. Therefore, cigarette smoking seems to improve the clopidogrel effectiveness. Meanwhile, cigarette smoking is a major risk factor for cardiovascular disease, and is associated with a fivefold increased risk of acute ST‐segment elevation myocardial infarction [21](#jcmm12797-bib-0021){ref-type="ref"}. Thus, the impact of cigarette smoking on clopidogrel effectiveness and disease prognosis remains unclear.

In this study, we tried to reveal the relationship between the CYP2C19\*2 genetic polymorphism and the outcome of the AMI patients who received clopidogrel treatment, and to further clarify the impact of cigarette smoking on such relationship.

Materials and methods {#jcmm12797-sec-0002}
=====================

Participants {#jcmm12797-sec-0003}
------------

Between January 2008 and December 2011, a total of 600 patients with confirmed AMI in the Fourth Hospital of Harbin Medical University were included. Inclusion criteria were predefined as follows: (1) Ischaemic type chest pain lasting for more than 20 min., (2) Elevation of ST segment on electrocardiogram, and change in serial electrocardiogram tracing, (3) Rise of serum cardiac biomarkers [22](#jcmm12797-bib-0022){ref-type="ref"}, [23](#jcmm12797-bib-0023){ref-type="ref"}.

Smoking history in AMI patients must meet one of the following three conditions: (1) Current smoking: smoking more than 10 years (\>10 cigarettes daily), and smoking within 4 weeks of AMI, (2) Former smoking: smoking more than 10 years (\>10 cigarettes daily) and smoking cessation within 1 year of AMI, (3) Non‐smoking: never smoking in their lives.

The exclusion criteria were as follows: (1) Active haemorrhage or haemorrhagic tendency, such as peptic ulcer, haemorrhagic stroke and purpura, (2) Severe anaemia (Haemoglobin ≤ 70 g/l), (3) Liver dysfunction (Albumin \< 30 g/l, Total bilirubin \> 34.2 μmol/l, Alanine transaminase \> 80 U/l, Aspartate transaminase \> 80 U/l), (4) Renal impairment (Serum creatinine \> 200 μmol/l), (5) Surgery or injury within the preceding 12 weeks, (6) Other serious diseases, such as tumour, infection, epilepsy, depression and mental disease, (7) Clopidogrel and aspirin intolerance, (8) Long‐term proton pump inhibitor usage, (9) Receive any antiplatelet or anticoagulant therapy in the last 4 weeks, (10) Smoking history did not meet any one of the conditions mentioned above.

Three hundred age‐ and gender‐matched healthy controls were randomly selected from the medical staff in the Fourth Hospital of Harbin Medical University. Written informed consent was obtained from all included patients and controls. This study was approved by the ethics committees of the Fourth Hospital of Harbin Medical University.

All patients received standard treatment. Each of them was treated with a dose of 300 mg clopidogrel and 300 mg aspirin before PCI. During the interventional procedure, at least one coronary stent was placed in the culprit vessel. To prevent recurrent ischaemic events, each patient was required to take clopidogrel (75 mg daily) and aspirin (100 mg daily) during the follow‐up period.

Genetic polymorphism detection {#jcmm12797-sec-0004}
------------------------------

Blood samples were obtained from all participants and were stored in tubes containing ethylene diamine tetraacetic acid. The genomic DNA was extracted using a commercial DNA isolation kit (Promega, WI, USA) according to the instruction manuals. The CYP2C19\*2 polymorphism was detected by polymerase chain reaction (PCR) -- restriction fragment length polymorphism (RFLP) analysis. The forward primer of CYP2C19\*2 alleles was 5′‐ ACC AGA GCT TGG CAT ATT GTA TCT‐3′, and the reverse primer of such alleles was 5′‐GAT TCT TGG TGT TCT TTT ACT TTC T‐3′. Both primers were provided by BGI Beijing Corporation. The PCR was performed according to the standard procedures: (1) Initial denaturation at 94°C for 5 min., (2) 35 cycles of denaturation at 94°C for 30 sec., (3) Annealing at 60°C for 30 sec., (4) Elongation at 72°C for 30 sec.; (5) Final extension at 72°C for 10 min. The PCR‐amplified products were digested with SmaI restriction enzyme (Takara biotechnology, Dalian, China) and submitted for direct DNA sequencing.

Platelet function assays {#jcmm12797-sec-0005}
------------------------

Each patient provided two blood samples for platelet function assay. One was obtained before clopidogrel administration. Another was obtained 72 hrs after clopidogrel administration and at least 24 hrs after termination of GP IIb/IIIa inhibitor treatment. All blood samples were stored in test tubes containing 3.8% sodium citrate, and were tested within 2 hrs.

The blood sample was centrifuged at 1000 r.p.m. for 10 min., and the resulting plasma was called as platelet‐rich plasma (PRP). After removing PRP, the sample was further centrifuged at 3000 r.p.m. for 5 min., and the resulting plasma was called as platelet‐poor plasma (PPP). The platelets were stimulated with 20 μmol/l adenosine diphosphate (ADP), and the platelet aggregation was assessed using a 4‐channel LBY‐NJ4 aggregometer (Precil, Beijing, China). The results were calculated according to the formula: (maximal light transmission of PRP/maximal light transmission of PPP) × 100%.

Information collection {#jcmm12797-sec-0006}
----------------------

All patients and controls were interviewed by a single trained investigator, and the demographic data, smoking history and other necessary information were obtained in the conversations. The medical information were collected from medical records. The patients were followed up for 5 years (60 months) or until death. The primary outcome was death as a result of recurrent myocardial infarction. The secondary outcome was recurrent angina, non‐fatal AMI, stent thrombosis and cerebral stroke. The tertiary outcome was haemorrhage. BARC haemorrhage standard definition was used, and Bleeding Academic Research Consortium (BARC) type 1 to type 5 were all counted as haemorrhage outcome [24](#jcmm12797-bib-0024){ref-type="ref"}.

Statistical analyses {#jcmm12797-sec-0007}
--------------------

All statistical analyses were performed performed with SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). Hardy--Weinberg genetic equilibrium test was used to estimate population representativeness. Statistical differences were assessed using independent sample *t*‐test in continuous variables and were tested using chi‐square test in categorical variables. *P* value \< 0.05 was considered to be statistical significance. The odds ratio (OR) with 95% confidence interval (CI) was calculated using multivariable logistic regression analysis. If the 95% CI did not include '1′, the OR was considered statistically significant.

Results {#jcmm12797-sec-0008}
=======

A total of 600 AMI patients and 300 health controls were included. All patients had completed 5‐year (60 months) follow‐up period or had been followed up until death. As shown in Table [1](#jcmm12797-tbl-0001){ref-type="table-wrap"}, the gender, age and ethnic group were equivalent between the patients and the controls (*P* = 0.254, *P* = 0.410 and *P* = 0.815). Compared with the controls, there were more patients with CYP2C19 681 mutant homozygotes (AA) (*P* \< 0.001) and less patients with CYP2C19 681 wild‐type homozygotes (GG) (*P* = 0.004). In addition, the frequencies of the CYP2C19\*2 genotypes obeyed the Hardy--Weinberg equilibrium in the patients (*P* = 0.331) and the health controls (*P* = 0.095).

###### 

Characteristics of the participants in the study

                              Patients     Controls     *P* value
  --------------------------- ------------ ------------ -----------
  No. of participants (*n*)   600          300          ―
  Gender, Male (*n*)          432          205          0.254
  Age (years, mean ± S.D.)    62.1 ± 6.7   61.7 ± 6.9   0.410
  Ethnic group, Han (*n*)     574          288          0.815
  Smoking history                                       
  Current smoking (*n*)       335          151          0.119
  Former smoking (*n*)        106          68           0.073
  Non‐smoking (*n*)           159          81           0.873
  CYP2C19\*2 genotype                                   
  GG (*n*, %)                 287 (47.8)   174 (58.0)   0.004
  GA (*n*, %)                 225 (37.5)   113 (37.7)   0.961
  AA (*n*, %)                 88 (14.7)    13 (4.3)     0.000

GG: CYP2C19 681 wild‐type homozygotes; GA: CYP2C19 681 mutant heterozygotes; AA: CYP2C19 681 mutant homozygotes.

John Wiley & Sons, Ltd

The patients were also stratified by smoking history, and were divided into three groups: current smoking group, former smoking group and non‐smoking group. The results of the platelet function assay were shown in Figure [1](#jcmm12797-fig-0001){ref-type="fig"}. In the non‐smoking group and the former smoking group, there were significant increased in ADP‐induced platelet aggregation percentage in the patients with AA genotypes compared with than in the patients with GG genotypes (GG: 42.3 ± 8.6%, AA: 54.1 ± 10.4%, *P* \< 0.001 and GG: 40.1 ± 8.1%, AA: 52.9 ± 9.7%, *P* \< 0.001). However, the difference between such two genotype groups was not observed in the current smoking patients (GG: 42.8 ± 8.9%, AA: 43.2 ± 8.3%, *P* = 0.112).

![Adenosine diphosphate (concentration 20 μmol/l) induced platelet aggregation stratified by smoking history. GG:CYP2C19 681 wild‐type homozygotes, GA:CYP2C19 681 mutant heterozygotes. AA:CYP2C19 681 mutant homozygotes. The horizontal line within each box represents the median. The lower and upper borders of each box represent the 25th and the 75th percentiles. The vertical line extends from the minimum to the maximum value.](JCMM-20-1247-g001){#jcmm12797-fig-0001}

Of the included patients, 414 patients survived and 186 patients died during the follow‐up period. The demographic information, disease history and treatment history of the survival patients and the death patients were shown in Table [2](#jcmm12797-tbl-0002){ref-type="table-wrap"}. It was worth noting that a greater proportion of non‐smoking patients survived (*P* \< 0.001), compared with the current smoking patients and the former smoking patients (*P* = 0.019 and *P* = 0.034).

###### 

Characteristics of the patients in the survival group and the death group

                                 Survival      Death         *P* value
  ------------------------------ ------------- ------------- -----------
  No. of participants (*n*, %)   414 (100.0)   186 (100.0)   ―
  Male (*n*, %)                  302 (72.9)    130 (69.9)    0.441
  Age (years, mean ± S.D.)       59.7 ± 5.8    67.3 ± 5.5    0.003
  Han (*n*, %)                   396 (95.7)    178 (95.7)    0.979
  BMI (kg/m^2^, mean ± S.D.)     24.0 ± 1.2    26.9 ± 1.2    0.000
  Hypertension (*n*, %)          201 (48.6)    129 (69.4)    0.000
  Diabetes (*n*, %)              144 (34.8)    82 (44.1)     0.030
  Hyperlipidaemia (*n*, %)       247 (59.7)    131 (70.4)    0.012
  CVD (*n*, %)                   73 (17.6)     58 (31.2)     0.000
  Drinking (*n*, %)              62 (15.0)     48 (25.8)     0.002
  Aspirin (*n*, %)               343 (82.9)    165 (88.7)    0.065
  Beta‐blocker (*n*, %)          376 (90.8)    133 (71.5)    0.000
  ACEI/ARB (*n*, %)              327 (79.0)    119 (64.0)    0.000
  Statins (*n*, %)               352 (85.0)    147 (79.0)    0.070
  Prior PCI (*n*, %)             34 (8.2)      47 (25.3)     0.000
  Prior CABG (*n*, %)            21 (5.1)      35 (18.8)     0.000
  Current smoking (*n*, %)       218 (52.7)    117 (62.9)    0.019
  Former smoking (*n*, %)        64 (15.5)     42 (22.6)     0.034
  Non‐smoking (*n*, %)           132 (31.9)    27 (14.5)     0.000

BMI: Body mass index; CVD: cerebrovascular disease; ACEI/ARB: Angiotensin‐converting enzyme inhibitor/Angiotensin receptor blocker; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting.

John Wiley & Sons, Ltd

As shown in Table [3](#jcmm12797-tbl-0003){ref-type="table-wrap"}, there were more survival patients with GG genotype and more death patients with AA genotype in the non‐smoking group (*P* \< 0.001) and the former smoking group (*P* = 0.020). But in the current smoking group, GG and AA genotype distributions were similar between the survival patients and the death patients (*P* = 0.619).

###### 

CYP2C19 681 genotypes of the patients in the survival group and the death group stratified by smoking history

  Smoking history   Prognosis   Total (*n*)   Genotypes[a](#jcmm12797-note-0004){ref-type="fn"}   *P* value[b](#jcmm12797-note-0005){ref-type="fn"}   *P* value[c](#jcmm12797-note-0006){ref-type="fn"}           
  ----------------- ----------- ------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ------- -------
  Current smoking   Survival    218           98                                                  85                                                  35                                                  0.815   0.619
  Death             117         50            46                                                  21                                                                                                              
  Former smoking    Survival    64            42                                                  18                                                  4                                                   0.168   0.020
  Death             42          19            15                                                  8                                                                                                               
  Non‐smoking       Survival    132           70                                                  51                                                  11                                                  0.285   0.000
  Death             27          8             10                                                  9                                                                                                               

GG: CYP2C19 681 wild‐type homozygotes, GA: CYP2C19 681 mutant heterozygotes, AA: CYP2C19 681 mutant homozygotes.

GG group *versus* GA group.

GG group *versus* AA group.

John Wiley & Sons, Ltd

During the follow‐up period, compared with the patients with GG genotype, more AA genotype patients in the non‐smoking and the former smoking groups suffered from adverse cardiovascular events, such as recurrent angina (OR: 4.63, 95% CI: 1.56--8.85 and OR: 3.66, 95% CI: 1.57--8.51), AMI (OR: 4.15, 95% CI: 1.16--7.24 and OR: 2.05, 95% CI: 1.09--5.03), stent thrombosis (OR: 5.17, 95% CI: 1.09--9.41 and OR: 3.79, 95% CI: 1.18--6.71) and cerebral stroke (OR: 4.44, 95% CI: 1.65--9.33 and OR: 3.39, 95% CI: 1.52--6.74). But in the current smoking group, the onset of the adverse cardiovascular events were similar between GG and AA genotype groups. The detailed results were shown in Table [4](#jcmm12797-tbl-0004){ref-type="table-wrap"}.

###### 

Association between the CYP2C19 681 genotypes and the adverse cardiovascular events stratified by smoking history

                     Multivariable adjusted OR (95% CI)[a](#jcmm12797-note-0007){ref-type="fn"}                       
  ------------------ ---------------------------------------------------------------------------- ------------------- -------------------
  Recurrent angina                                                                                                    
  GG                 Reference                                                                    Reference           Reference
  GA                 1.02 (0.49, 1.64)                                                            1.54 (0.86, 4.57)   3.39 (0.64, 5.15)
  AA                 1.18 (0.79, 1.93)                                                            3.66 (1.57, 8.51)   4.63 (1.56, 8.85)
  Recurrent AMI                                                                                                       
  GG                 Reference                                                                    Reference           Reference
  GA                 1.27 (0.51, 3.51)                                                            2.00 (0.31, 4.73)   3.17 (0.65, 5.24)
  AA                 1.30 (0.69, 2.72)                                                            2.05 (1.09, 5.03)   4.15 (1.16, 7.24)
  Stent thrombosis                                                                                                    
  GG                 Reference                                                                    Reference           Reference
  GA                 0.71 (0.43, 1.59)                                                            2.97 (0.32, 6.48)   4.97 (0.89, 7.73)
  AA                 0.95 (0.68, 1.93)                                                            3.79 (1.18, 6.71)   5.17 (1.09, 9.41)
  Cerebral stroke                                                                                                     
  GG                 Reference                                                                    Reference           Reference
  GA                 0.82 (0.47, 1.71)                                                            3.16 (0.78, 5.29)   2.98 (0.93, 5.88)
  AA                 0.76 (0.48, 1.85)                                                            3.39 (1.52, 6.74)   4.44 (1.65, 9.33)

OR (95% CI): Odds ratio (95% confidence interval). Multivariable adjusted OR were adjusted for age, body mass index, onset of hypertension, diabetes, hyperlipidaemia, cerebrovascular disease, drinking, beta‐blocker usage, angiotensin‐converting enzyme inhibitor usage, angiotensin receptor blocker usage, prior percutaneous coronary intervention and prior coronary artery bypass grafting.

CI: confidence interval; GG: CYP2C19 681 wild‐type homozygotes; GA: CYP2C19 681 mutant heterozygotes; AA: CYP2C19 681 mutant homozygotes; AMI: Aute myocardial infarction.

John Wiley & Sons, Ltd

In the non‐smoking and the former smoking groups, after adjusted for multiple confounding factors, the 5‐year mortalities of the AA genotype patients increased compared with the GG genotype patients (OR: 7.06, 95% CI: 2.16--11.49 and OR: 4.38, 95% CI: 1.05--9.40). But no such change was found in the current smoking group (OR: 1.12, 95% CI: 0.60--2.31). The patients were also divided into two subgroups according to the haemorrhage history during the follow‐up period. The results did not change, which revealed that the impact of smoking on the prognosis was independent of the haemorrhage history. The detailed results were shown in Table [5](#jcmm12797-tbl-0005){ref-type="table-wrap"}.

###### 

Association between the CYP2C19 681 genotypes and the death during the follow‐up period stratified by smoking history

                    Multivariable adjusted OR (95% CI)[a](#jcmm12797-note-0009){ref-type="fn"}                       
  ----------------- ---------------------------------------------------------------------------- ------------------- --------------------
  Total                                                                                                              
  GG                Reference                                                                    Reference           Reference
  GA                1.05 (0.61, 1.69)                                                            1.79 (0.68, 4.22)   1.52 (0.53, 4.27)
  AA                1.12 (0.60, 2.31)                                                            4.38 (1.05, 9.40)   5.06 (2.16, 11.49)
  Haemorrhage                                                                                                        
  GG                Reference                                                                    Reference           Reference
  GA                1.12 (0.52, 1.77)                                                            1.67 (0.59, 4.51)   1.12 (0.87, 3.87)
  AA                1.09 (0.48, 2.17)                                                            4.21 (1.14, 8.37)   5.79 (1.91, 7.33)
  Non‐haemorrhage                                                                                                    
  GG                Reference                                                                    Reference           Reference
  GA                1.21 (0.39, 1.94)                                                            1.72 (0.61, 4.18)   1.33 (0.51, 4.80)
  AA                1.16 (0.53, 2.11)                                                            4.00 (1.01, 9.03)   6.88 (2.00, 11.16)

OR (95% CI): Odds ratio (95% confidence interval). Multivariable adjusted OR were adjusted for age, body mass index, onset of hypertension, diabetes, hyperlipidaemia, cerebrovascular disease, drinking, beta‐blocker usage, angiotensin‐converting enzyme inhibitor usage, angiotensin receptor blocker usage, prior percutaneous coronary intervention and prior coronary artery bypass grafting.

CI: confidence interval; GG: CYP2C19 681 wild‐type homozygotes; GA: CYP2C19 681 mutant heterozygotes; AA: CYP2C19 681 mutant homozygotes.

John Wiley & Sons, Ltd

Discussion {#jcmm12797-sec-0009}
==========

In the study, we enrolled 600 AMI patients and 300 health controls, completed 5 years follow‐up period, and tried to reveal the association between the onset of the CYP2C19 681 mutant genotypes and the poor prognosis in AMI patients. Several evidence supporting the hypothesis had been found mainly in the non‐smoking and the smoking cessation population. First, there were more CYP2C19 681 gene mutation (AA genotype) in AMI patients than in controls, which showed the potential relationship between CYP2C19 681 genotype and the onset of AMI. Second, when the patients were treated with antiplatelet drug clopidogrel, the platelets showed better aggregation function in the AA genotype patients. Third, the patients with AA genotypes were more prone to adverse cardiovascular events during the follow‐up period. Fourth, after excluding the effects of multiple confounding factors, 5‐year survival incidence was significantly higher in the patients without mutant genotypes compared with the patients with AA genotypes. Therefore, based on the results in the study, the CYP2C19\*2 polymorphism might be a potential marker for the prognosis in AMI patients.

However, most positive results mentioned above were not observed in the current smoking patients in our study. Possible mechanisms were as follows: (1) The CYP1A2 was another important metabolic enzyme, which could promote the activation of clopidogrel, (2) Cigarette smoking was able to elevate the expression of the CYP1A2 and to improve the efficacy of clopidogrel, (3) This might partly counteract the effect of the CYP2C19 681 gene mutation. Years ago, Bliden *et al*. conducted a study suggesting that clopidogrel therapy in current smokers was associated with increased platelet inhibition and lower aggregation [20](#jcmm12797-bib-0020){ref-type="ref"}. This research was consistent with our study. Therefore, cigarette smoking might weaken the prognostic significance of the CYP2C19 in AMI patients. However, further study should be conducted to explore the detailed mechanisms.

Based on our results, cigarette smoking might partly increase the efficacy of clopidogrel. But this did not mean that smoking could improve the prognosis of AMI patients. As we all know, long‐term smoking could seriously damage blood vessels, and lead to vascular stenosis and heart attack [25](#jcmm12797-bib-0025){ref-type="ref"}, [26](#jcmm12797-bib-0026){ref-type="ref"}, [27](#jcmm12797-bib-0027){ref-type="ref"}. At least half of long‐term smokers died earlier as a result of smoking [28](#jcmm12797-bib-0028){ref-type="ref"}, [29](#jcmm12797-bib-0029){ref-type="ref"}. Therefore, the efficacy of clopidogrel apparently could not compensate for the systemic damage caused by long‐term smoking. Our study achieved consistent results. As shown in Table [2](#jcmm12797-tbl-0002){ref-type="table-wrap"}, a greater proportion of non‐smoking patients survived during the follow‐up period, compared with the current smoking patients. Undoubtedly, Smoking was extremely harmful to health, and was related with poor prognosis in cardiovascular disease patients.

In the study, the patients were divided into three smoking history groups including the former smoking group. Previous study suggested that the time course of CYP1A2 activity changes after smoking cessation in heavy smokers was not entirely clear [30](#jcmm12797-bib-0030){ref-type="ref"}. To avoid bias, 'the former smoking' was defined as 'smoking more than 10 years (\>10 cigarettes daily), and smoking cessation within 1 year of AMI'.

Mature and reliable technology was adopted in the study. The CYP2C19\*2 polymorphism was detected by PCR--RFLP analysis, and the platelet function was assessed using conventional aggregometry. A great many of previous studies focused on the relationship between CYP2C19 polymorphism and clopidogrel therapy -- related diseases also adopted these technologies, and reported comparable results [31](#jcmm12797-bib-0031){ref-type="ref"}, [32](#jcmm12797-bib-0032){ref-type="ref"}. These might support the validity of our detection on the CYP2C19\*2 polymorphism and the platelet function.

There were several limitations in the study. On the one hand, we did not study other CYP P450 isoenzymes and their genetic polymorphism, particularly CYP1A2, which affected the metabolism of clopidogrel. On the other hand, our study was not a randomized controlled trial, and could not rule out the influence of selection bias. Therefore, some randomized controlled studies which included a variety of clopidogrel‐related metabolic enzymes should be conducted.

In conclusion, our study suggested a potential role of CYP2C19\*2 polymorphism as a prognostic indicator in AMI patients. We had also obtained some interesting evidence that cigarette smoking might weaken the prognostic significance of the genetic polymorphism in patients. In addition, though cigarette smoking might improve the efficiency of clopidogrel, it was still related with poor prognosis in cardiovascular disease patients and was extremely harmful to health.
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